The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with…
EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed…
SUNNYVALE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for…
TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting…
Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin ExtractVancouver,…
The myTomorrows platform now also features embedded AI eligibility checking and usability improvements, further streamlining the clinical trial and Expanded…
HONG KONG, Dec. 17, 2024 /PRNewswire/ -- Great Bay Bio (GBB) is thrilled to announce the successful first close of its…
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from…
Hoggan Receives Vital Recredentialing for Microfet Product Line SALT LAKE CITY, UTAH / ACCESSWIRE / December 16, 2024 / Hoggan…
Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU PatientsResults Expected to Promote Awareness and Adoption of PKU…